Headquartered in Sydney, NRM Corporation trades under trade name AMI.
Sexual Health Treatments
Treatment options are generally provided under a treatment program (3-24 months).
As part of its treatment programs, AMI arranges for a fully licensed pharmacy to fill its patients’ individual prescriptions and supply medications to those patients.
We are also in the initial stages of developing new methods of treatment delivery.
AMI’s Path Breaking Research and Development
Australian Sexual Dysfunction market
Information published by the research firm IMS in October 2006 estimated the Australian Erectile Dysfunction market to have AUD$63 million (approximately $47.25 million) in annual sales (Australian Financial Review, October 23, 2006, page 50).
Our efforts to penetrate the market for its Premature Ejaculation treatment programs has expanded our revenue base. Prior to these efforts starting in October 2004, AMI did not directly advertise or market its Premature Ejaculation treatment programs, the sole focus had been on the Erectile Dysfunction market. AMI’s Erectile Dysfunction treatment programs predominantly focus on men aged 40 and over whereas AMI’s Premature Ejaculation treatment programs are targeted at a broader market (men aged 18 and over). AMI changed its marketing focus during fiscal 2005 to target the broader market for its Premature Ejaculation treatment programs whilst continuing to offer and separately market Erectile Dysfunction treatment programs.
About 90,000 Australian men are expected to develop impotence each year and all up 1 million Australian men face the prospect of needing this type of assistance (West Australian March 8, 2004, page 12).
AMI expects continued growth in its Premature Ejaculation and Erectile Dysfunction treatment programs during the course of calendar 2009 and calendar 2010.
Worldwide Sexual Dysfunction market
It has been estimated that worldwide 152 million men suffer from erection problems with the number being anticipated to reach 304 million by 2020 (1st international consultation on Erectile Dysfunction, July 1-3, 1999 and Hartmut Porst, Restoring a Normal Sexual Response: The Ultimate Goal of Erectile Dysfunction Therapy, European Urology Supplements, volume 1, November 8, 2002, page 1924, also reported in the Australian Financial Review, October 2, 2004, page 25).
The U.S. Food and Drug Administration (“FDA”) advisory committee reports that there are over 30 million impotent men in the United States and 30 million Europeans with this condition. This equates to approximately 20% of the male population in these areas.
Studies conducted in Europe and Australia discovered that 75% – 88% of men with Erectile Dysfunction had not sought treatment. Effective oral Erectile Dysfunction therapies such as Sildenafil (Viagra **), Vardanafil (Levitra *)* and Tadalafil (Cialis **) are now well established and effective treatments, for some men. Many others with existing medical conditions such as coronary heart disease, diabetes and high blood pressure are unable to take advantage of these standard treatment methods.
Medications that need to be swallowed must be absorbed from the gastrointestinal tract. Unlike rivals such as Viagra *, Levitra * and Cialis *, AMI's most pharmacological formulations are not affected by food intake as the medications are not delivered through the gastrointestinal system. This delivers AMI a substantial medical and commercial advantage and results in a 95 – 98% treatment success rate.
Latest filed financial statements by Pfizer, Eli lily and Bayer, the leading worldwide providers of Erectile Dysfunction medications, show more than $3 billion in total annual revenue relating to these medications.
There are no figures available on the worldwide sale of Premature Ejaculation products as the market appears to be relatively untapped with no current competitive products to AMI's Australian Premature Ejaculation product.
Based on its experience in selling Premature Ejaculation treatment programs in Australia AMI anticipates the worldwide PE market to be substantial and to be of at least the same size as the Erectile Dysfunction market.
The Future of AMI
Based on publicly available Australian and Worldwide market information, the Sexual Dysfunction market share we have achieved in Australia and our analysis of the regulatory and market opportunities available in the United States and elsewhere, we are extremely excited by our prospects and our opportunities for growth in the coming years.
**Viagra * –trademark of Pfizer, Levitra *-Bayer ,Cialis * –ELlilly
Advanced Medical Institute